Are you over 18 and want to see adult content?
More Annotations
Off Campus Student Housing Near USC | University Gateway
Are you over 18 and want to see adult content?
Discounts on console games — Official Stores
Are you over 18 and want to see adult content?
PUBR Noticias › Noticias do Brasil e do Mundo em tempo real
Are you over 18 and want to see adult content?
Destin Beach Vacation Rentals Desitn Things To Do
Are you over 18 and want to see adult content?
Being the Best YOU You Can Be
Are you over 18 and want to see adult content?
Licota.ru - официальный сайт профессионального инструмента Licota (Ликота)
Are you over 18 and want to see adult content?
Scholars Official - Designing future
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of watsonian-squire.com
Are you over 18 and want to see adult content?
A complete backup of brasileirao2017.club
Are you over 18 and want to see adult content?
A complete backup of stadtwerke-landshut.de
Are you over 18 and want to see adult content?
A complete backup of job-prices.co.uk
Are you over 18 and want to see adult content?
A complete backup of thegreatfroglondon.com
Are you over 18 and want to see adult content?
A complete backup of new-age-gamer.com
Are you over 18 and want to see adult content?
A complete backup of howtoshiftyourincome.com
Are you over 18 and want to see adult content?
A complete backup of cardboard-crack.com
Are you over 18 and want to see adult content?
Text
SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential accessINVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to the required licensing, GECA Pharma will in future form the pharmaceutical branch of SynBiotic SE.ALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. ADHOC | SYNBIOTIC SE: ZEICHNUNG EINER …TRANSLATE THIS PAGE AdHoc | SynBiotic SE: Zeichnung einer Wandelanleihe in Höhe von US$ 2.000.000,- und Abschluss eines Call-Option-VertragsSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential accessINVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to the required licensing, GECA Pharma will in future form the pharmaceutical branch of SynBiotic SE.ALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. ADHOC | SYNBIOTIC SE: ZEICHNUNG EINER …TRANSLATE THIS PAGE AdHoc | SynBiotic SE: Zeichnung einer Wandelanleihe in Höhe von US$ 2.000.000,- und Abschluss eines Call-Option-Vertrags PORTFOLIO | SYNBIOTIC Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVEST | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactWWW.SYNBIOTIC.COM
www.synbiotic.com
6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential accessINVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to the required licensing, GECA Pharma will in future form the pharmaceutical branch of SynBiotic SE.ALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. ADHOC | SYNBIOTIC SE: ZEICHNUNG EINER …TRANSLATE THIS PAGE AdHoc | SynBiotic SE: Zeichnung einer Wandelanleihe in Höhe von US$ 2.000.000,- und Abschluss eines Call-Option-VertragsSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential accessINVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to the required licensing, GECA Pharma will in future form the pharmaceutical branch of SynBiotic SE.ALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. ADHOC | SYNBIOTIC SE: ZEICHNUNG EINER …TRANSLATE THIS PAGE AdHoc | SynBiotic SE: Zeichnung einer Wandelanleihe in Höhe von US$ 2.000.000,- und Abschluss eines Call-Option-Vertrags PORTFOLIO | SYNBIOTIC Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVEST | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactWWW.SYNBIOTIC.COM
www.synbiotic.com
6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have huge medical potential.In addition, the so called entourage effectis a term used to describe the synergistic effects of combining various chemical compounds found in cannabis.Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM Munich, April 6, 2021. The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future value creationABOUT | SYNBIOTIC
Following his post-doctoral research, Le Roy became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy holds a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University(2002).
INVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625ALL ADHOC RELEASES
München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.CONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money.SYNBIOTIC
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have huge medical potential.In addition, the so called entourage effectis a term used to describe the synergistic effects of combining various chemical compounds found in cannabis.Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes. SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM Munich, April 6, 2021. The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future value creationABOUT | SYNBIOTIC
Following his post-doctoral research, Le Roy became Quality Assurance Officer for Ulster’s Biomedical Sciences Research Institute (BMSRI). Le Roy holds a BSc (Hons) in Biochemistry from Queen’s University, Belfast and a PhD in Nutritional Biochemistry at Ulster University(2002).
INVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625INVESTORS & PRESS
WKN: A2LQ77. ISIN: DE000A2LQ777. Ticker Symbol: SBX. Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX. Total number of shares: 2.625.000. Share capital: 2.625ALL ADHOC RELEASES
München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.CONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
INVEST | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact 2020-12-01 SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact VICUPETS | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
INVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
INVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.ALL PRESS RELEASES
SynBiotic SE und The Hempany wollen mit Hanfmilch „hemi“ den Markt für pflanzenbasierte Milchalternativen erobern. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. The private bank Hauck & Aufhäuser was committed as a designatedADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to the required licensing, GECA Pharma will in future form the pharmaceutical branch of SynBiotic SE.INVEST | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact IMPRINT | SYNBIOTICTRANSLATE THIS PAGE SynBiotic SE. Barer Str. 7 80333 München office@synbiotic.com. Geschäftsführender Direktor: Lars Müller. Vorsitzender des Verwaltungsrats: Dipl.-Kfm. SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
INVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen Arm SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021.SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
INVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen Arm SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC SE NOW ALSO LISTED ON THE FRANKFURT STOCK Munich, January 7, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVEST | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW. IMPRINT | SYNBIOTICTRANSLATE THIS PAGE SynBiotic SE. Barer Str. 7 80333 München office@synbiotic.com. Geschäftsführender Direktor: Lars Müller. Vorsitzender des Verwaltungsrats: Dipl.-Kfm. SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
HALBJAHRESBERICHT
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. © 2021 Synbiotic SE | All rights reserved. Imprint Privacy policy Privacy policy ELEMENTOR-POST-SCREENSHOT_140_2021-04-05-15-15-16_4E306C8 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money.SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
VICUPETS | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactELEMENT-1-1.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactLEANLABS-LOGO.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money.SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
VICUPETS | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactELEMENT-1-1.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactLEANLABS-LOGO.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactSYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money.SYNBIOTIC
SynBiotic Approach. Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.ABOUT | SYNBIOTIC
Research & Development. Our R&D portfolio will create new products, formulations and IP and conduct studies to: Create innovative products which we are well-positioned to bring to market. Grow SynBiotic as the leading name and expert in the industry. We execute minority share investments in these companies, in order to get preferential access SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions, SynBiotic SE is continuing expansion of its important research and development division, which is expected to account for a large part of the company’s future valuecreation.
SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactINVESTORS & PRESS
München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen ArmCONTACT | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactALL ADHOC RELEASES
AdHoc | SynBiotic SE: Sachkapitalerhöhung zur Übernahme der Lean Labs Pharma GmbH und Restgeschäftsanteil Solidmind Nutrition GmbH beschlossen. München (pta052/20.04.2021/18:05) – Insiderinformation gem. Artikel 17 MAR (Ad hoc-Mitteilung) NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG INNERHALB DER BZW.INVESTORS & PRESS
Growth: Wir wachsen Jahr für Jahr um 75% (20% organisch, 55% anorganisch) Strategie: Wir decken mit unserer Buy & Build-Strategie die gesamte Cannabinoid-Wertschöpfungskette ab und. konsolidieren die stärksten Akteure der Branche unter einem Dach. SynBiotic SE teilt sich in folgende Verticals: 1) D2C & medizinische Marken. SYNBIOTIC SE BECOMES THE FIRST PUBLICLY TRADED COMPANY IN Munich, February 16, 2021. Given the excessive increase in money supply in both the euro and USD zones, there is legitimate concern about a massive devaluation of fiat money. SYNBIOTIC – DECK – MAY 2021 SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SHAREHOLDER-STRUCTURE SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SOLIDMIND | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact SYNBIOTIC SE AND THE HEMPANY SEEK TO CONQUER THE MARKET Munich, March 9, 2021. For many years, consumers have been looking for alternatives to classic cow’s milk. Oat milk has become particularlypopular here.
VICUPETS | SYNBIOTIC SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactADDRESS–V2
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactDATA PROTECTION
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact6.JPG | SYNBIOTIC
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactELEMENT-1-1.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; ContactLEANLABS-LOGO.PNG
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. Imprint Privacy policy. SynBiotic; About; Investors & Press; Contact* SynBiotic
* About
* Investors & Press
* Contact
__ Menü
* SynBiotic
* About
* Investors & Press
* Contact
__
* SynBiotic
* About
* Investors & Press
* Contact
__ Menü
* SynBiotic
* About
* Investors & Press
* Contact
__
Europe’s #1 ecosystem for cannabinoid & terpene based solutions With our EU focused buy & build strategy we cover the whole cannabinoid value chain and transform ideas into better brands & products for multi-billion markets like pain, sleep & anxiety. __ why we are different __ investor relations- ( L3DA )
- - ( 0.00% )
FOCUS ON REAL CONSUMER PROBLEMS. People are looking for solutions to their real-life problems. With cannabinoids we are able to address a multi-billion EU-market for sleep, pain and anxiety solutions with cumulative sales of over € 250 billion for OTC and pharmaceuticals in 2020.over
0
people with sleep-related problems, such as disturbed sleepover
0
people with chronic pain and similar issuesover
0
PEOPLE WITH ANXIETY
SYNBIOTIC VALUE CHAIN SynBiotic’s organizational structure is built to cover all value drivers – from research over production to distribution__
RESEARCH & DEVELOPMENT Our R&D portfolio consists of leading research facilities, whose scientists are sought-after pioneers in the field of cannabinoids.__
PRODUCTION & BIOTECH With a portfolio of production and extraction companies operating cutting-edge facilities, we can guarantee products of the highest quality – a significant competitive advantage.__
DISTRIBUTION
We buy and build strong medical & DTC brands which enable us to distribute our innovative products to customers.OUR COMPANIES
SYNBIOTIC APPROACH
BEYOND CANNABIS FOR A MULTI-BILLION MARKET. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential. WHY? – BECAUSE WE WANT TO BUILD THE MOST EFFECTIVE PRODUCTS IN THEMARKET
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have HUGE MEDICAL POTENTIAL. In addition, the so called ENTOURAGE EFFECTis a term used to describe the synergistic effects of combining various chemical compounds found in cannabis. Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes. _* CBX = all cannabinoids except THC_ BEYOND CANNABIS & HEMP While CBD from hemp & cannabis plants is still a legal grey area, we focus in parallel on other plants that are rich in cannabinoids, endocannabinoids & terpenes. WE ANALYSED OVER 1000 PLANTS AND SEARCHED FOR CANNABINOIDS, ENDOCANNABINOIDS & TERPENES ... ... AND WE FOUND MANY. BE A PART OF OUR MISSIONFOR VENTURES
SynBiotic supports & invests in cannabinoid focused ventures and teams. Are you looking for a strong partner? Contact us!FOR INVESTORS
Find out more about our company, its structure, shares and download the latest financial publications. Investor RelationsPRESS
SYNBIOTIC SE ACQUIRES GECA PHARMA AND ENTERS THE MEDICAL CANNABISMARKET
Munich, May 18th 2021. The cannabis company SynBiotic SE has taken over 100 percent of the Cologne-based GECA Pharma GmbH. With its expert knowledge allied to theread more...
19. Mai 2021 11:50
SYNBIOTIC SE ÜBERNIMMT GECA PHARMA: EINSTIEG IN DEN MARKT FÜR MEDIZINISCHES CANNABIS München, 18. Mai 2021. Das Cannabis-Unternehmen SynBiotic SE übernimmt die Kölner GECA Pharma GmbH zu 100 Prozent. Die GECA Pharma wird mit ihrem Expertenwissen sowie den notwendigen Lizenzen künftig den pharmazeutischen Armread more...
19. Mai 2021 6:15
SYNBIOTIC SE SECURES CANADIAN CANNABINOID AND R&D PLATFORM NEUROTHERYX CANADA LTD Munich, April 6, 2021. The cannabis company SynBiotic SE is joining NeuroTheryX Canada Ltd (NeuroTheryX) and securing a complete takeover of its R&D platform by April1, 2023. With these decisions,read more...
6. April 2021 18:10
__
back to top
- ( L3DA )
- - ( 0.00% )
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE. 2021 Synbiotic SE | All rights reserved Imprint Privacy policyDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0